



Guardant Health held a sponsored session, *Putting the Patient First: A Fireside Chat on the Promise and Challenges of Blood-Based Cancer Screening* as part of the Virtual Dialogue webcast Series, [Part 2: Innovative Technologies to Expand Cancer Screening](#) on June 24, 2020. The questions below were asked in the Q&A text feature during the live webcast session but not answered, due to time constraints. Guardant has provided us with answers, and we share that information with you here.

Question	Response
Would a colonoscopy still be needed for abnormal exam, like the FIT test?	Yes, the LUNAR-2 test is intended to be a screening test, not a diagnostic test.
Can patients reach you all directly if they want to participate?	Yes! Please visit our website at https://guardanthealth.com/eclipse/ to learn more about the study, study sites, and to contact us.
Can the blood test for colorectal cancer be used in high risk populations?	Not at this time, the LUNAR-2 test is currently being studied for use in individuals at average risk for CRC.
I think one of the issues for some patients is that they fear if they get a positive test then they will have to go in for the more invasive test which will now be considered a diagnostic and will incur more expensive fees. How can this be remedy or has it been discussed?	Guardant understands this is an issue and is committed to working alongside leading organizations and policymakers to reduce CRC screening barriers.
Are the results of your researches and studies shared with public or any government agencies? Is your company currently working with any government agencies or programs?	Guardant has had conversations with the Food & Drug Administration (FDA) and the Centers for Medicare & Medicaid Services (CMS) about the ECLIPSE study. Additional information regarding Guardant's on-going research efforts can be found on our website at: link .